In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Adjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically ...

Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of ...